Abstract
Infectious diseases in the skin represent a major group of pathologies that contribute annually for significant health economic expenses. According to WHO, Buruli Ulcer (BU) and Cutaneous Leishmaniasis (CL) are two neglected tropical diseases for which therapy remains inadequate. Topical delivery of therapeutics constitutes an advantageous alternative to treat infected skin lesions as it allows a direct treatment of affected areas avoiding unwanted systemic effects and reducing the drug dosage. However, effective topical delivery of antimicrobial agents is still a challenge. The emergence of difficult-to-treat skin mycobacteriosis such as BU or the increasing incidence of CL highlights the need for new antimicrobial agents and new delivery systems. In the present review problems related to mycobacterial and parasitic infected skin lesions will be particularly focused as well as new alternative strategies for their treatment. Currently, progresses and challenges in constructing nanocarrier platforms for delivering various antimicrobial drugs for infected skin lesions have been attempted. This article reviews the potential of these nanocarriers in the treatment of cutaneous infections, especially regarding mycobacteria and Leishmania caused skin lesions. Nanostructured biomaterials, such as lipid-based nanocarriers, have unique physicochemical properties enabling the topical application of antimicrobial drugs, thereby overcoming some of the limitations of conventional therapies. These nanosystems have been investigated for the topical delivery of well-known drugs or new therapeutic candidates. This approach is just the beginning of a stimulating nanotechnological area.
Keywords: Lipid-based nanocarriers, Topical drug delivery, Skin infections, Buruli ulcer, Cutaneous leishmaniasis, Neglected tropical diseases.
Current Pharmaceutical Design
Title:Lipid-Based Nanocarriers for Cutaneous Leishmaniais and Buruli Ulcer Management
Volume: 22 Issue: 43
Author(s): Sandra Simoes, Manuela Carvalheiro and Maria Manuela Gaspar
Affiliation:
Keywords: Lipid-based nanocarriers, Topical drug delivery, Skin infections, Buruli ulcer, Cutaneous leishmaniasis, Neglected tropical diseases.
Abstract: Infectious diseases in the skin represent a major group of pathologies that contribute annually for significant health economic expenses. According to WHO, Buruli Ulcer (BU) and Cutaneous Leishmaniasis (CL) are two neglected tropical diseases for which therapy remains inadequate. Topical delivery of therapeutics constitutes an advantageous alternative to treat infected skin lesions as it allows a direct treatment of affected areas avoiding unwanted systemic effects and reducing the drug dosage. However, effective topical delivery of antimicrobial agents is still a challenge. The emergence of difficult-to-treat skin mycobacteriosis such as BU or the increasing incidence of CL highlights the need for new antimicrobial agents and new delivery systems. In the present review problems related to mycobacterial and parasitic infected skin lesions will be particularly focused as well as new alternative strategies for their treatment. Currently, progresses and challenges in constructing nanocarrier platforms for delivering various antimicrobial drugs for infected skin lesions have been attempted. This article reviews the potential of these nanocarriers in the treatment of cutaneous infections, especially regarding mycobacteria and Leishmania caused skin lesions. Nanostructured biomaterials, such as lipid-based nanocarriers, have unique physicochemical properties enabling the topical application of antimicrobial drugs, thereby overcoming some of the limitations of conventional therapies. These nanosystems have been investigated for the topical delivery of well-known drugs or new therapeutic candidates. This approach is just the beginning of a stimulating nanotechnological area.
Export Options
About this article
Cite this article as:
Simoes Sandra, Carvalheiro Manuela and Gaspar Manuela Maria, Lipid-Based Nanocarriers for Cutaneous Leishmaniais and Buruli Ulcer Management, Current Pharmaceutical Design 2016; 22 (43) . https://dx.doi.org/10.2174/1381612822666160701083812
DOI https://dx.doi.org/10.2174/1381612822666160701083812 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolic and Cardiovascular Ageing Indices in Relation to Glycated Haemoglobin in Healthy and Diabetic Subjects
Current Aging Science Positive Social Interactions in a Lifespan Perspective with a Focus on Opioidergic and Oxytocinergic Systems: Implications for Neuroprotection
Current Neuropharmacology Partial A1 Adenosine Receptor Agonists from a Molecular Perspective and Their Potential Use as Chronic Ventricular Rate Control Agents During Atrial Fibrillation (AF)
Current Topics in Medicinal Chemistry Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Current Topics in Medicinal Chemistry Visceral Adiposity Measurements, Metabolic and Inflammatory Profi le in Obese Patients with and Without Type 2 Diabetes Mellitus: A Crosssectional Analysis
Current Diabetes Reviews Crosslinked, Polymerized, and PEG-Conjugated Hemoglobin-Based Oxygen Carriers: Clinical Safety and Efficacy of Recent and Current Products
Current Drug Discovery Technologies COX-2 and the Kidneys
Current Pharmaceutical Design Protein Z and Ischemic Stroke
Vascular Disease Prevention (Discontinued) Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease
Current Alzheimer Research Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?
Current Pharmaceutical Design The Role of Zebrafish in Chemical Genetics
Current Medicinal Chemistry HIV-Induced Abnormalities in Myelopoiesis and their Recovery Following Antiretroviral Therapy
Current HIV Research Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Biological Strategies to Enhance Rotator Cuff Healing.
Current Stem Cell Research & Therapy Is there any Additional Prognostic Value of Central Blood Pressure Wave Forms Beyond Peripheral Blood Pressure?
Current Pharmaceutical Design Analytical Methods for the Identification of Pigments in Tattoo Inks and Some of Their Physiological Side Effects: A Review
Current Pharmaceutical Analysis Chemistry, Physiology, and Pharmacology of β-Adrenergic Mechanisms in the Heart. Why are β-Blocker Antiarrhythmics Superior?
Current Pharmaceutical Design Molecular Predictors of Drug-induced Prolongation of the QT Interval
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Aminoacid Support in the Prevention of Diabetes and Diabetic Complications
Current Protein & Peptide Science